Table 3.

Results from included studies (primary and secondary outcomes).

StudyComplete RemissionPrimary OutcomesSecondary Efficacy Outcomes
Partial RemissionOverall RemissionESRDDeath
MMF Events/TotalCYC Events/TotalMMF Events/TotalCYC Events/TotalMMF Events/TotalCYC Events/TotalMMF Events/TotalCYC Events/TotalMMF Events/TotalCYC Events/Total
Ginzler1416/714/6921/7117/6937/7121/694/717/694/718/69
Chan1624/3323/318/337/3132/3330/310/332/310/332/31
Ong185/193/256/1910/2511/1913/251/192/251/191/25
Appel1716/18515/185104/18598/185120/185113/1857/18515/1859/1855/185
StudySecondary Safety Outcomes
InfectionsLeukopeniaAnemiaGastrointestinalHerpes ZosterAmenorrheaAlopecia
MMF Events/TotalCYC Events/TotalMMF Events/TotalCYC Events/TotalMMF Events/TotalCYC Events/TotalMMF Events/TotalCYC Events/TotalMMF Events/TotalCYC Events/TotalMMF Events/TotalCYC Events/TotalMMF Events/TotalCYC Events/Total
Ginzler144/7111/69Not reported2/712/6938/7127/693/714/690/712/690/718/69
Chan168/3326/310/338/31Not reported3/331/312/335/311/339/310/339/31
Ong186/196/257/1913/25Not reported9/1910/253/193/250/191/25Not reported
Appel17126/185111/18511/18538/18523/18512/185123/185186/18523/18512/1851/1858/18520/18564/185
  • MMF: mycophenolate mofetil; CYC: cyclophosphamide; ESRD: endstage renal disease.